A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-14

Study Completion Date

2022-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM). Patients were evaluated for eligibility during the Screening Period. Eligible patients were stratified by diagnosis of DM or PM and randomized 1:1 to Arm A or Arm B of the study.

During the 32-week treatment period, patients received study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each.

This study was conducted on an outpatient basis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

NCT04628936

Polymyositis Dermatomyositis

COMPLETED PHASE2

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

NCT03600818

Polymyalgia Rheumatica

TERMINATED PHASE3

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

NCT05669014

Idiopathic Inflammatory Myositis

COMPLETED PHASE2

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020

Dermatomyositis

TERMINATED PHASE2/PHASE3

A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

NCT06306339

Moderate to Severe Rheumatoid Arthritis

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polymyositis Dermatomyositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Intervention Type DRUG

Subcutaneous injection for 16 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KZR-616

Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks

Intervention Type DRUG

Placebo

Subcutaneous injection for 16 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

zetomipzomib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult patients at least 18 years of age
2. Body Mass Index (BMI) of 18 to 40 kg/m\^2
3. Diagnosis of probable or definite DM or PM by the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria
4. Must have their data reviewed by an adjudication committee to confirm eligibility unless at least 1 of the following is present:

1. Muscle biopsy with evidence of active myositis within the last 6 months prior to or at Screening
2. Electromyography or magnetic resonance imaging with evidence of active myositis within the last 6 months prior to Screening
3. A creatine kinase (CK) ≥4 × upper limit of normal (ULN).
5. Must have demonstrable muscle weakness as measured by the Manual Muscle Testing-8 muscle Groups (MMT-8) with a score ≥80/150 but ≤136/150 units and any 2 of the following:

1. Physician Global Assessment (MDGA) visual analog scale (VAS) ≥2 cm
2. Patient Global Assessment of Disease Activity (PtGADA) VAS ≥2 cm
3. At least one muscle enzyme laboratory measurement ≥1.3 × ULN
4. Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Global Activity VAS ≥1 cm.
6. Documented inadequate response OR have demonstrated documented toxicity or intolerance to prior standard of care therapies
7. Has had age-appropriate cancer screening that is up to date and negative for evidence of malignancy as per local standard of care

Exclusion Criteria

1. Has significant muscle damage or has a muscle damage VAS score ≥5 cm on the MDI
2. Any other form of myositis or myopathy other than PM or DM
3. Any condition that precludes the ability to quantitate muscle strength
4. Has severe interstitial lung disease or has a pulmonary damage VAS score ≥5 cm on the Myositis Damage Index (MDI)
5. Presence of autoinflammatory disease
6. Use of nonpermitted medications or treatments within the specified washout periods prior to screening
7. Patient has had recent serious or ongoing infection, or risk for serious infection
8. Any of the following laboratory values at Screening:

1. Estimated glomerular filtration rate \<45 mL/min
2. Hemoglobin \<10 g/dL
3. White blood cell (WBC) count \<3.0 × 10\^9/L
4. Absolute neutrophil count (ANC) \<1.5 × 10\^9/L (1500/mm\^3)
5. Platelet count \<100 × 10\^9/L
6. Serum AST or serum ALT \>2.5 × ULN (unless considered consistent with muscle origin)
7. Serum alkaline phosphatase \>2.5 × ULN
8. Total bilirubin \>1.5 × ULN (3 × ULN for patients with documented Gilbert's syndrome)
9. Thyroid stimulating hormone outside of the central laboratory normal range
10. Immunoglobulin G (IgG) \<500 mg/dL.
9. Presence of New York Heart Association Class III or IV heart failure, or uncontrolled blood pressure, or prolonged QT interval
10. Major surgery within 12 weeks before Screening or planned during the study period
11. Clinical evidence of significant unstable or uncontrolled diseases
12. Any active or suspected malignancy, including myeloproliferative or lymphoproliferative disorder, or history of documented malignancy within the last 5 years before Screening or within 3 years of diagnosis of myositis, except appropriately excised and cured cervical carcinoma in situ or basal or squamous cell carcinoma of the skin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No